We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

356 hedge funds and large institutions have $15.8B invested in Alnylam Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 125 increasing their positions, 129 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 129

5% less capital invested

Capital invested by funds: $16.5B → $15.8B (-$744M)

7% less call options, than puts

Call options by funds: $121M | Put options by funds: $131M

3.68% less ownership

Funds ownership: 97.24% → 93.55% (-3.7%)

5% less funds holding

Funds holding: 374 → 356 (-18)

13% less funds holding in top 10

Funds holding in top 10: 8 → 7 (-1)

35% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 49

Holders
356
Holders Change
-18
Holders Change %
-4.81%
% of All Funds
7.18%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.14%
New
32
Increased
125
Reduced
129
Closed
49
Calls
$121M
Puts
$131M
Net Calls
-$9.8M
Net Calls Change
-$52.2M

Top Buyers

1
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$120M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$34.5M
3
FCM
Farallon Capital Management
California
+$21.3M
4
Norges Bank
Norges Bank
Norway
+$19.6M
5
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$10.6M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$86.1M
2
Goldman Sachs
Goldman Sachs
New York
-$70.7M
3
SPC
Slate Path Capital
New York
-$52.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$52.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$47.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
NERM
376
New England Research & Management
Illinois
– -$607K -4,100 Closed
APA
377
American Portfolios Advisors
New York
– -$531K -3,586 Closed
CANY
378
Caxton Associates (New York)
New York
– -$508K -3,431 Closed
BS
379
Banco Santander
Spain
– -$508K -3,429 Closed
HS
380
HighVista Strategies
Massachusetts
– -$415K -2,805 Closed
ALAM
381
Asahi Life Asset Management
Japan
– -$353K -2,380 Closed
AC
382
Athanor Capital
New York
– -$340K -2,296 Closed
CI Investments Inc
383
CI Investments Inc
Ontario, Canada
– -$302K -2,036 Closed
Verition Fund Management
384
Verition Fund Management
Connecticut
– -$258K -1,743 Closed
MYAM
385
Meiji Yasuda Asset Management
Japan
– -$218K -1,470 Closed
CCP
386
Corient Capital Partners
California
– -$216K -1,460 Closed
ACM
387
AlphaCrest Capital Management
New York
– -$210K -1,421 Closed
PAG
388
Private Advisor Group
New Jersey
– -$103K -693 Closed
ClearBridge Investments
389
ClearBridge Investments
New York
– -$54K -365 Closed
AS
390
Altshuler Shaham
Israel
– -$29K -198 Closed
SWM
391
Selective Wealth Management
Virginia
– -$13K -88 Closed
OPS
392
Orion Portfolio Solutions
Nebraska
– -$11K -75 Closed
SF
393
Synovus Financial
Georgia
– -$6K -39 Closed
CFG
394
Citizens Financial Group
Rhode Island
– -$5K -37 Closed
ABC
395
Associated Banc-Corp
Wisconsin
– -$5K -33 Closed
SSB
396
Sandy Spring Bank
Maryland
– -$4K -25 Closed
BWM
397
BerganKDV Wealth Management
Minnesota
– -$3K -19 Closed
BL
398
Balentine LLC
Georgia
– -$2K -16 Closed
WAM
399
Wolverine Asset Management
Illinois
– -$1K -13 Closed
BWA
400
BDO Wealth Advisors
Florida
– -$1K -5 Closed
13 14 15
16
17

ALNY Hedge Fund Activity: Q3 2020 in Review

356 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2020, worth a combined $15.8B — down 4.5% from $16.5B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ALNY and 32 opened new positions — a net loss of 17 holders — while 129 trimmed existing stakes and 125 added.

The largest buyer was Massachusetts Financial Services, adding an estimated $120M. The largest seller was Fidelity Investments, cutting an estimated $86.1M.

  • 356 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2020, down from 374 in Q2 2020.
  • Funds reported $15.8B of Alnylam Pharmaceuticals stock for Q3 2020, down 4.5% quarter-over-quarter.
  • 32 funds opened new Alnylam Pharmaceuticals positions in Q3 2020 and 49 closed out, a net change of -17 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2020 was Massachusetts Financial Services, an estimated $120M added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $86.1M sold.

Based on aggregated 13F filings for Q3 2020.